Life Tech Expands Synthetic Biology Portfolio with TAL Effector License | GenomeWeb

By Bernadette Toner

NEW YORK (GenomeWeb News) – Life Technologies said today that it has signed an exclusive license agreement for technology that enables synthetic biologists to selectively modify the gene expression of genetically engineered organisms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.